Skip to main content
. 2015 Mar 10;17(7):992–998. doi: 10.1093/neuonc/nov011

Table 3.

Summary of worst dasatinib-related adverse event per participant

Adverse Event CTCAE Grade Stage 1 (n = 21) Stage 1B (n = 29)
Worst nonhematological 1 4 (19%) 6 (21%)
2 8 (38%) 12 (41%)
3 8 (38%) 5 (17%)
4 0 (0%) 1 (3%)
5 0 (0%) 0 (0%)
Worst overall 1 0 (0%) 5 (17%)
2 8 (38%) 11 (38%)
3 12 (57%) 8 (28%)
4 0 (0%) 1 (3%)
5 0 (0%) 0 (0%)

Includes adverse events in which relationship to protocol treatment is missing.